secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001645113-23-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Q3 net revenues $127.3M (-3% YoY); net loss $49.5M as INNOVATE-3 misses endpoint
--------------------------------------------------------------------------------

- Net revenues $127.3M, down 3% YoY; US contributed $86.2M, Germany $14.7M, Japan $7.6M.
- Net loss $49.5M ($0.46 loss per share); adjusted EBITDA $(29.1)M.
- 3,639 active patients on therapy as of Sept 30, 2023; prescriptions up 6% YoY to 1,467.
- Phase 3 INNOVATE-3 (ovarian cancer) did not meet primary overall survival endpoint at final analysis.
- Cash & short-term investments $921.2M; gross margin 75%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/0001645113-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/nvcr-20231026.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer